This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The viral hepatitis market size has grown steadily in recent years. It will grow from $16.21 billion in 2024 to $16.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.
The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.97 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.
The increasing prevalence of hepatitis is expected to drive the growth of the viral hepatitis market in the coming years. Hepatitis refers to a liver infection caused by various infectious viruses and non-infectious substances, leading to several health complications. Hepatitis A, B, C, D, and E are some of the viruses responsible for viral hepatitis, which causes liver inflammation and damage. For example, in April 2024, the European Centre for Disease Prevention and Control, a government health agency based in Sweden, reported 28,855 cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% increase from the 16,187 cases recorded in 2021. Furthermore, the total number of cases in 2022, which amounted to 28,420, represented a crude rate of 8.5 cases per 100,000 people. Therefore, the growing prevalence of hepatitis will fuel the expansion of the viral hepatitis market.
The increasing volume of research and development (R&D) endeavors is expected to serve as a powerful growth driver for the viral hepatitis market. Research and development initiatives focused on viral hepatitis encompass a wide spectrum of activities, including the development of vaccines, antiviral medications, diagnostic tests, epidemiological studies, public health interventions, genomic research, prevention strategies, global health campaigns, clinical trials, and investigations into co-infections. The upsurge in R&D activities not only fosters innovation in treatment approaches but also expands the array of options for diagnosis and prevention. This, in turn, leads to a higher number of clinical trials, stronger global health initiatives, and heightened competition among pharmaceutical companies. For instance, in November 2022, researchers in Melbourne secured funding of $1.7 million for the next five years through the mRNA Victoria Activation Program. This funding is set to advance their pioneering work in the quest for a cure for hepatitis B virus infection. Consequently, the escalation in the number of research and development activities is a driving force behind the growth of the viral hepatitis market.
Prominent companies active in the viral hepatitis market are dedicated to advancing the development of new drugs to reinforce their position within the market. The pursuit of drug development and innovation serves to enrich scientific understanding by shedding light on disease mechanisms, thus expediting the creation of novel treatments. For instance, in November 2022, Gilead Sciences Inc., a biopharmaceutical company based in the United States, disclosed the FDA's granting of the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. These tablets are designed for once-daily administration to address chronic hepatitis B virus (HBV) infection in pediatric patients aged 12 years and older with compensated liver disease. The approval for Vemlidy's utilization in this specific group of pediatric patients was backed by the results of a 24-week Phase 2 clinical trial.
In November 2023, GSK plc, a pharmaceuticals company based in the U.K., acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. With the acquisition of the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug, GSK aims to enhance its portfolio and reinforce its position in the chronic hepatitis B treatment space by adding a new and potentially valuable therapy. Janssen Pharmaceuticals, a Belgium-based subsidiary of Johnson & Johnson, is known for developing treatments for infectious diseases, including chronic hepatitis B.
Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.
North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral hepatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.
The viral hepatitis market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral hepatitis market also includes the sales of treatments such as vaccines and medication. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Viral hepatitis encompasses a group of infectious diseases resulting from various viruses (hepatitis A, B, C, D, and E), primarily affecting the liver. The symptoms may vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting, and fever.
The primary types of viral hepatitis diseases include hepatitis A, hepatitis B, hepatitis C, and others. Hepatitis A is a potentially life-threatening liver ailment caused by the hepatitis A virus. Diagnosis is typically achieved through liver biopsy, blood tests, imaging tests, and other diagnostic methods. Treatment options involve antiviral drugs, surgery, vaccines, immune modulator drugs, and others. These treatments can be administered through various routes, including oral and parenteral, and are commonly offered in hospitals, specialty clinics, homecare settings, and other relevant healthcare facilities.
The viral hepatitis market research report is one of a series of new reports that provides viral hepatitis market statistics, including viral hepatitis industry global market size, regional shares, competitors with a viral hepatitis market share, detailed viral hepatitis market segments, market trends and opportunities and any further data you may need to thrive in the viral hepatitis industry. This viral hepatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The viral hepatitis market size has grown steadily in recent years. It will grow from $16.21 billion in 2024 to $16.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.
The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.97 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.
The increasing prevalence of hepatitis is expected to drive the growth of the viral hepatitis market in the coming years. Hepatitis refers to a liver infection caused by various infectious viruses and non-infectious substances, leading to several health complications. Hepatitis A, B, C, D, and E are some of the viruses responsible for viral hepatitis, which causes liver inflammation and damage. For example, in April 2024, the European Centre for Disease Prevention and Control, a government health agency based in Sweden, reported 28,855 cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% increase from the 16,187 cases recorded in 2021. Furthermore, the total number of cases in 2022, which amounted to 28,420, represented a crude rate of 8.5 cases per 100,000 people. Therefore, the growing prevalence of hepatitis will fuel the expansion of the viral hepatitis market.
The increasing volume of research and development (R&D) endeavors is expected to serve as a powerful growth driver for the viral hepatitis market. Research and development initiatives focused on viral hepatitis encompass a wide spectrum of activities, including the development of vaccines, antiviral medications, diagnostic tests, epidemiological studies, public health interventions, genomic research, prevention strategies, global health campaigns, clinical trials, and investigations into co-infections. The upsurge in R&D activities not only fosters innovation in treatment approaches but also expands the array of options for diagnosis and prevention. This, in turn, leads to a higher number of clinical trials, stronger global health initiatives, and heightened competition among pharmaceutical companies. For instance, in November 2022, researchers in Melbourne secured funding of $1.7 million for the next five years through the mRNA Victoria Activation Program. This funding is set to advance their pioneering work in the quest for a cure for hepatitis B virus infection. Consequently, the escalation in the number of research and development activities is a driving force behind the growth of the viral hepatitis market.
Prominent companies active in the viral hepatitis market are dedicated to advancing the development of new drugs to reinforce their position within the market. The pursuit of drug development and innovation serves to enrich scientific understanding by shedding light on disease mechanisms, thus expediting the creation of novel treatments. For instance, in November 2022, Gilead Sciences Inc., a biopharmaceutical company based in the United States, disclosed the FDA's granting of the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. These tablets are designed for once-daily administration to address chronic hepatitis B virus (HBV) infection in pediatric patients aged 12 years and older with compensated liver disease. The approval for Vemlidy's utilization in this specific group of pediatric patients was backed by the results of a 24-week Phase 2 clinical trial.
In November 2023, GSK plc, a pharmaceuticals company based in the U.K., acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. With the acquisition of the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug, GSK aims to enhance its portfolio and reinforce its position in the chronic hepatitis B treatment space by adding a new and potentially valuable therapy. Janssen Pharmaceuticals, a Belgium-based subsidiary of Johnson & Johnson, is known for developing treatments for infectious diseases, including chronic hepatitis B.
Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.
North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral hepatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.
The viral hepatitis market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral hepatitis market also includes the sales of treatments such as vaccines and medication. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Viral hepatitis encompasses a group of infectious diseases resulting from various viruses (hepatitis A, B, C, D, and E), primarily affecting the liver. The symptoms may vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting, and fever.
The primary types of viral hepatitis diseases include hepatitis A, hepatitis B, hepatitis C, and others. Hepatitis A is a potentially life-threatening liver ailment caused by the hepatitis A virus. Diagnosis is typically achieved through liver biopsy, blood tests, imaging tests, and other diagnostic methods. Treatment options involve antiviral drugs, surgery, vaccines, immune modulator drugs, and others. These treatments can be administered through various routes, including oral and parenteral, and are commonly offered in hospitals, specialty clinics, homecare settings, and other relevant healthcare facilities.
The viral hepatitis market research report is one of a series of new reports that provides viral hepatitis market statistics, including viral hepatitis industry global market size, regional shares, competitors with a viral hepatitis market share, detailed viral hepatitis market segments, market trends and opportunities and any further data you may need to thrive in the viral hepatitis industry. This viral hepatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Viral Hepatitis Market Characteristics3. Viral Hepatitis Market Trends and Strategies4. Viral Hepatitis Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Viral Hepatitis Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Viral Hepatitis Market34. Recent Developments in the Viral Hepatitis Market
5. Global Viral Hepatitis Growth Analysis and Strategic Analysis Framework
6. Viral Hepatitis Market Segmentation
7. Viral Hepatitis Market Regional and Country Analysis
8. Asia-Pacific Viral Hepatitis Market
9. China Viral Hepatitis Market
10. India Viral Hepatitis Market
11. Japan Viral Hepatitis Market
12. Australia Viral Hepatitis Market
13. Indonesia Viral Hepatitis Market
14. South Korea Viral Hepatitis Market
15. Western Europe Viral Hepatitis Market
16. UK Viral Hepatitis Market
17. Germany Viral Hepatitis Market
18. France Viral Hepatitis Market
19. Italy Viral Hepatitis Market
20. Spain Viral Hepatitis Market
21. Eastern Europe Viral Hepatitis Market
22. Russia Viral Hepatitis Market
23. North America Viral Hepatitis Market
24. USA Viral Hepatitis Market
25. Canada Viral Hepatitis Market
26. South America Viral Hepatitis Market
27. Brazil Viral Hepatitis Market
28. Middle East Viral Hepatitis Market
29. Africa Viral Hepatitis Market
30. Viral Hepatitis Market Competitive Landscape and Company Profiles
31. Viral Hepatitis Market Other Major and Innovative Companies
35. Viral Hepatitis Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Viral Hepatitis Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on viral hepatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for viral hepatitis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viral hepatitis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Hepatitis A: Acute Hepatitis A; Chronic Hepatitis A2) By Hepatitis B: Acute Hepatitis B; Chronic Hepatitis B; Hepatitis B Carrier
3) By Hepatitis C: Acute Hepatitis C; Chronic Hepatitis C
4) By Other Disease Types: Hepatitis D; Hepatitis E
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Co; F Hoffmann-La Roche AG; Merck & Co.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Viral Hepatitis market report include:- Pfizer Inc.
- Johnson & Johnson Co
- F Hoffmann-La Roche AG
- Merck & Co.
- AbbVie Inc.
- Novartis AG
- Sanofi SA
- Bristol-Myers Squibb
- Astra Zeneca Pharmaceuticals LP
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Gilead Sciences Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Daiichi Sankyo Co. Ltd.
- Hetero Drugs Ltd.
- Eisai Co. Ltd.
- Boehringer Ingelheim Group
- Sun Pharmaceutical Industries Ltd.
- Lupin Limited
- Dr. Reddy's Laboratories
- Zydus Lifescience Ltd.
- Glenmark Pharmaceuticals Ltd.
- Cipla Ltd.
- Torrent Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Wockhardt Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 16.93 Billion |
| Forecasted Market Value ( USD | $ 19.97 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
